Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,088 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,119
- Phase 1824
- Phase 1/Phase 2483
- Phase 3350
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma334
- Acute Myeloid Leukemia291
- Lymphoma183
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Anemia62
- Mantle Cell Lymphoma62
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center59
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama147
- Arizona123
- Florida110
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,088 total
- NCT07514819Recruiting
Adaptive Proton Therapy Planning for Children With Cancer
This study tests a new way to plan proton radiation therapy (a precise type of cancer treatment) for children with solid tumors or Hodgkin's lymphoma. The goal is to improve how doctors adapt treatment during therapy to better target tumors while protecting healthy tissue.
Memphis, TennesseeAges Any age - NCT07332507RecruitingPhase 1
Testing teclistamab for recurrent plasmablastic lymphoma
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT05263284RecruitingPhase 1
Study of 8-chloroadenosine plus venetoclax for relapsed or refractory AML
This trial tests a combination of two drugs, 8-chloroadenosine and venetoclax, for people with acute myeloid leukemia (AML) that has come back or not responded to prior treatments. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT07288489RecruitingPhase 3
A study on VMX-C001 for urgent surgery while on blood thinners
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
Chandler, ArizonaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Birmingham, AlabamaAges Up to 12 months - NCT04419649RecruitingPhase 2
Elritercept for anemia in lower-risk myelodysplastic syndromes
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
Hot Springs, ArkansasAges 18 years+ - NCT04563520RecruitingPhase 3
Testing the safety of aPCC after emicizumab in hemophilia A
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Atlanta, GeorgiaAges 6 years+ - NCT07613385Recruiting
Personalized Treatment Plan for Relapsed or Resistant AML
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07532941RecruitingPhase 4
Stopping antibiotics early versus completing the full course
This study compares two ways of giving antibiotics to children: stopping when symptoms feel better versus finishing all the prescribed doses. Researchers want to see if stopping early is safe and works just as well, which could help reduce unnecessary antibiotic use.
Melbourne, VictoriaAges 1–17 - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Phoenix, ArizonaAges birth–20 years - NCT07455851RecruitingPhase 1/Phase 2
Studying a new drug combo for relapsed or refractory multiple myeloma
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
Randwick, New South WalesAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT07631598Recruiting
Buprenorphine at Needle Exchange Programs to Prevent Overdoses
This study tests whether offering buprenorphine (a medication that reduces cravings and withdrawal) directly at syringe service programs (places where people get clean needles) can help people with opioid addiction stay safe and reduce overdose risk. If you use opioids and visit a syringe service program, this may be an option to explore.
Los Angeles, CaliforniaAges 18 years+ - NCT05893940Recruiting
Gentle physical stimulation during blood cancer transplant
This trial tests whether a low-intensity mechanical (physical) stimulation is safe and helpful for people with certain blood cancers who are about to have a transplant. It may affect how you do during or after treatment, and participation is voluntary with informed consent.
Buffalo, New YorkAges 18 years+ - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Gilbert, ArizonaAges 18 years+ - NCT07429266RecruitingPhase 3
Study of sapablursen for phlebotomy-dependent polycythemia vera
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
Miami, FloridaAges 18 years+ - NCT05579132RecruitingPhase 1/Phase 2
Study drug for relapsed or hard-to-treat B-cell leukemia
This early study tests MK-1045 in people with precursor B-cell acute lymphoblastic leukemia (B-ALL) that has come back or did not respond to earlier treatment. It may help shrink leukemia and improve remission in patients with limited options.
Chongqing, Chongqing MunicipalityAges 2 years+ - NCT07112378RecruitingPhase 3
Study of dupilumab for young children with eosinophilic esophagitis
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Phoenix, ArizonaAges 6 months–6 years - NCT07400029RecruitingPhase 2
Obecabtagene autoleucel for B-cell ALL in remission
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
Duarte, CaliforniaAges 40 years+ - NCT07514936RecruitingPhase 3
Venetoclax-Azacitidine With Chidamide and CAG for Older AML Patients
This trial tests a combination of four drugs (venetoclax, azacitidine, chidamide, and CAG chemotherapy) to treat newly diagnosed acute myeloid leukemia (AML—a blood cancer) in adults aged 60–75. The goal is to see if this combination helps patients live longer and feel better.
Beijing, None SelectedAges 60–75 - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT07609940RecruitingPhase 4
Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Los Angeles, CaliforniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,088 recruiting hematology studies from the U.S. registry right now, out of 7,677 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.